Skip to main content

Toxicity and patient-reported quality of life through 12 months following pelvis-inclusive once-weekly stereotactic body radiotherapy versus conventional IMRT for high-risk prostate cancer: updated results of the SRAM randomized phase II trial

In brief

Once-weekly prostate radiation lowered bowel quality-of-life scores at 9 and 12 months

In 121 men with high-risk prostate cancer, once-weekly stereotactic radiation and conventional radiation had similar rates of moderate or worse bowel and urinary toxicity from 6 to 12 months. But bowel quality-of-life scores were lower with stereotactic treatment at 9 and 12 months; whether this difference persists beyond a year remains unknown.

Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (Q1)
Published
11 November 2026
Study design
Phase 2 randomized trial (exploratory)
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Darren Mc Poon, Kenneth Cw Wong, Daisy Cm Lam, Cheuk-Fun Chan, Allen Cc Chen, David Johnson, et al.
PMID
43014569
DOI
10.1016/j.radonc.2026.111870

Why clinicians should know about it

Abstract

AIM: To compare toxicity through 12 months and patient-reported quality of life following pelvis-inclusive stereotactic body radiotherapy (SBRT) versus conventional intensity-modulated radiotherapy (IMRT) in men with high-risk prostate cancer enrolled in the SRAM trial (NCT03938649). METHODS: Men with node-negative high-risk prostate cancer were randomly assigned 1:1 to pelvis-inclusive SBRT or IMRT. SBRT was delivered 40 Gy to the prostate and 25 Gy to the pelvis in five once-weekly fractions; IMRT comprised 50 Gy to the prostate and pelvis followed by a 26 Gy prostate boost. Gastrointestinal (GI) and genitourinary (GU) toxicities were graded using Common Terminology Criteria for Adverse Events version 4.0. Patient-reported outcomes were assessed using the Expanded Prostate Cancer Index (EPIC) and International Prostate Symptom Score (IPSS). RESULTS: Among 121 evaluable patients, 60 received SBRT and 61 IMRT. Between 6 and 12 months after radiotherapy, grade ≥2 GI and GU toxicity occurred in 16.7 % versus 13.1 % (p = 0.583) and 11.7 % versus 16.4 % (p = 0.455) of patients, respectively, including one grade 3 rectal hemorrhage after SBRT. EPIC bowel scores were lower in the SBRT group at 9 months (83.2 vs. 92.4; p = 0.0022) and 12 months (82.5 vs. 90.1; p = 0.0181), reflecting greater declines from baseline. Other EPIC domains and IPSS outcomes were broadly similar between groups. CONCLUSION: Once-weekly pelvis-inclusive SBRT showed no significant difference in grade ≥2 GI and GU toxicity compared with conventional IMRT at 6-12 months, but was associated with worse patient-reported bowel quality of life at 9-12 months.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.